We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$958M
AUM Growth
+$3.46M
Cap. Flow
+$6.87M
Cap. Flow %
0.72%
Top 10 Hldgs %
27.27%
Holding
97
New
7
Increased
32
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.5M
2
MDT icon
Medtronic
MDT
+$8.92M
3
TECH icon
Bio-Techne
TECH
+$7.15M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.83M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.66M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$21.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$11M
3
UNH icon
UnitedHealth
UNH
+$8.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.62M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Industrials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
51
Natera
NTRA
$45.9B
$6.63M 0.69%
165,000
+85,000
+106% +$3.5M
ITCI
52
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.62M 0.69%
125,000
– –
KRTX
53
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.89M 0.62%
30,000
+10,000
+50% +$2.14M
WST icon
54
West Pharmaceutical
WST
$24.8B
$5.88M 0.61%
25,000
+8,000
+47% +$1.9M
ESPR
55
DELISTED
Esperion Therapeutics
ESPR
$5.61M 0.59%
900,000
– –
VEEV icon
56
Veeva Systems
VEEV
$38.1B
$5.57M 0.58%
34,500
– –
IOVA icon
57
Iovance Biotherapeutics
IOVA
$2.9B
$5.52M 0.58%
864,378
+354,378
+69% +$2.77M
NVST icon
58
Envista
NVST
$4.53B
$5.52M 0.58%
163,800
+20,000
+14% +$684K
EXAS
59
DELISTED
Exact Sciences
EXAS
$5.45M 0.57%
110,000
+34,000
+45% +$1.39M
OSH
60
DELISTED
Oak Street Health, Inc.
OSH
$5.38M 0.56%
+250,000
New +$5.23M
SGEN
61
DELISTED
Seagen Inc. Common Stock
SGEN
$5.27M 0.55%
41,000
– –
OLK
62
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$4.93M 0.51%
194,390
– –
PHR icon
63
Phreesia
PHR
$769M
$4.85M 0.51%
150,000
+25,000
+20% +$679K
VRAY
64
DELISTED
ViewRay, Inc.
VRAY
$4.48M 0.47%
1,000,000
– –
RCM
65
DELISTED
R1 RCM Inc. Common Stock
RCM
$4.14M 0.43%
378,000
– –
AGL icon
66
Agilon Health
AGL
$1.63B
$4.12M 0.43%
10,200
– –
IQV icon
67
IQVIA
IQV
$39.8B
$4.1M 0.43%
+20,000
New +$4.06M
ALKS icon
68
Alkermes
ALKS
$8.29B
$3.92M 0.41%
150,000
– –
ALHC icon
69
Alignment Healthcare
ALHC
$2.86B
$3.82M 0.4%
325,000
+50,050
+18% +$609K
GKOS icon
70
Glaukos
GKOS
$10.7B
$3.71M 0.39%
85,000
– –
MGTX icon
71
MeiraGTx Holdings
MGTX
$1.21B
$3.62M 0.38%
555,030
– –
TDOC icon
72
Teladoc Health
TDOC
$1.29B
$3.07M 0.32%
130,000
– –
RLAY icon
73
Relay Therapeutics
RLAY
$4.37B
$2.99M 0.31%
+200,000
New +$3.83M
ARVN icon
74
Arvinas
ARVN
$588M
$2.91M 0.3%
85,000
+35,000
+70% +$1.47M
TXG icon
75
10x Genomics
TXG
$7.63B
$2.73M 0.29%
75,000
– –
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rhenman & Partners Asset Management held 97 positions worth $958M, up 0.36% from $955M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q4 2022 filing shows 7 new, 32 increased, 18 reduced and 4 closed positions. Its largest new stake was Bio-Techne: 90,000 shares worth $7.46M. The largest sale was Abiomed Inc, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q4 2022 buy was Bio-Techne: 90,000 shares worth $7.46M.
  • Rhenman & Partners Asset Management added most to HCA Healthcare in Q4 2022, an estimated $10.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2022 reduction was Intuitive Surgical, cutting an estimated $11M.
  • Rhenman & Partners Asset Management fully exited Abiomed Inc in Q4 2022, selling an estimated $21.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $958M portfolio in Q4 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 4 in Q4 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 0.36% quarter-over-quarter to $958M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.